Literature DB >> 29874194

Clinical heterogeneity and molecular profile of triple A syndrome: a study of seven cases.

Kanika Singh1, Ratna Dua Puri1, Pratibha Bhai1, Archana Dayal Arya2, Garima Chawla2, Renu Saxena1, Ishwar C Verma1.   

Abstract

Background Triple A syndrome is characterized by achalasia, alacrima and adrenal insufficiency with neurological manifestations occurring later in the course of the disease. It occurs due to biallelic mutations in the AAAS gene which codes for the nuclear pore protein ALADIN. A number of other features have been reported over time in this heterogeneous and multisystemic disorder. Unlike other autosomal recessive disorders, triple A syndrome patients show a wide phenotypic variability both among different patients and family members harboring the same mutation(s). A gene-environment interaction has been thought to be a plausible cause. Methods A retrospective analysis of six families and seven patients presenting with triple A syndrome was carried out. The clinical, biochemical and molecular testing data were collected and correlated. The results of treatment and follow-up and genetic counseling of the families were obtained wherever feasible. Results Our cohort consisted mostly of children and displayed a wide phenotypic variability in the presenting symptoms ranging from hypoglycemic seizures at the severe end of the spectrum to insidious hyperpigmentation and delayed development. Neurological and autonomic features were present in a few patients, suggesting requirement of prolonged follow-up for these patients. A significant gap between the onset of symptoms and confirmatory diagnosis was noted, suggesting that a high index of suspicion is required for diagnosing this disorder. Sudden unexplained death was observed in siblings, and early diagnosis and treatment could help in preventing early mortality and improving the quality of life for these patients. Conclusion High index of suspicion for a potentially treatable disorder allows early appropriate intervention.

Entities:  

Keywords:  AAAS gene; Allgrove; achalasia; adrenal insufficiency; alacrima; triple A syndrome

Mesh:

Substances:

Year:  2018        PMID: 29874194     DOI: 10.1515/jpem-2018-0023

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  5 in total

1.  A Novel Variant in Triple A Syndrome.

Authors:  E Demet Akbaş; Ö Özalp Yüreğir; Ö Anlaş; Z Özçelik; O Zerrin Tolunay
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Jul-Sep       Impact factor: 0.877

2.  Functional validation of a novel AAAS variant in an atypical presentation of Allgrove syndrome.

Authors:  Erica L Macke; Joel A Morales-Rosado; Sarah K Macklin-Mantia; Christopher T Schmitz; Björn Oskarsson; Eric W Klee; Klaas J Wierenga
Journal:  Mol Genet Genomic Med       Date:  2022-05-15       Impact factor: 2.473

3.  Protein signature of human skin fibroblasts allows the study of the molecular etiology of rare neurological diseases.

Authors:  Andreas Hentschel; Artur Czech; Ute Münchberg; Erik Freier; Ulrike Schara-Schmidt; Albert Sickmann; Jens Reimann; Andreas Roos
Journal:  Orphanet J Rare Dis       Date:  2021-02-09       Impact factor: 4.123

4.  Bilateral Recurrent Laryngeal Nerve Palsy following Total Thyroidectomy in Triple A Syndrome, an Unexpected but Critical Complication.

Authors:  Mathieu Chamberland; Marc-Antoine Poulin; Danielle Beaudoin
Journal:  Case Rep Otolaryngol       Date:  2021-11-19

5.  Triple A syndrome presenting as complicated hereditary spastic paraplegia.

Authors:  Etienne Leveille; Hernan D Gonorazky; Marie-France Rioux; Lili-Naz Hazrati; Jennifer A Ruskey; Amanda Carnevale; Dan Spiegelman; Alexandre Dionne-Laporte; Guy A Rouleau; Grace Yoon; Ziv Gan-Or
Journal:  Mol Genet Genomic Med       Date:  2018-10-31       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.